The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
|Articles|April 13, 2021
New Therapeutic Targets in Non–Small Cell Lung Cancer: KRAS G12C
On February 3, 2021, OncLive® brought together a group of oncologists who specialize in the treatment of lung cancer to participate in a virtual workshop to discuss the emerging treatment landscape of targeted therapies in NSCLC. This article summarizes key data about KRAS G12C as a therapeutic target as well as insights from stakeholder discussions regarding this topic.
Advertisement
Advertisement
Related to this article
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.
The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.
First-line osimertinib plus gefitinib produced an 82.1% response rate and blocked second-site EGFR resistance mutations, but missed feasibility criteria.
Advertisement
Advertisement
Trending on OncLive
1
OSE2101 Plus Pembrolizumab as Maintenance Boosts PFS in Platinum-Sensitive Ovarian Cancer
2
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
3
The OncFive: Top Oncology Articles for the Week of 9/14/2026
4
FDA Grants Breakthrough Therapy Designation to First-Line Daraxonrasib Plus Chemo in mPDAC
5